Navigation Links
Prostate Cancer Therapeutics Market ; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Date:4/19/2017

NEW YORK, April 19, 2017 /PRNewswire/ -- Global Prostate Cancer Therapeutics Market: Overview

This report on the prostate cancer therapeutics market analyzes the current and future scenario of the global market. Increasing prevalence of prostate cancer, launch of promising emerging therapies, as well as innovation in the development of new drugs & therapeutic biological products, and high growth in hormone-refractory prostate cancer drug due to lesser side effects are some of the drivers expected to drive the global prostate cancer therapeutics market during the forecast period.

Read the full report: http://www.reportlinker.com/p04833605/Prostate-Cancer-Therapeutics-Market-Distribution-Channel-Hospital-Pharmacy-Retail-Pharmacy-and-Online-Sales-Global-Industry-Analysis-Size-Share-Growth-Trends-and-Forecast.html

The global prostate cancer therapeutics market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the country's market with respect to the segments based on therapy type, distribution channels and regions.

A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global prostate cancer therapeutics market.

Global Prostate Cancer Therapeutics Market: Key Segments
Based on therapy type, the market has been segmented into hormone therapy, chemotherapy, biologic therapy and targeted therapy. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference from oncologists for treating the prostate cancer with various drug classes. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Based on distribution channels, the global prostate cancer therapeutics market has been segmented into hospital pharmacy, retail pharmacy, online sales and others. The market segments have been extensively analyzed based on increase in demand for disease treatment among prostate cancer patients. Increased patient hospitalization for the treatment of prostate cancer are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year.

Global Prostate Cancer Therapeutics Market: Regional Outlook
Geographically, the global prostate cancer therapeutics market on the basis of region has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Companies Mentioned in Report
The report also profiles major players in the global prostate cancer therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include players in the global prostate cancer therapeutics market are Amgen, Inc., Johnson & Johnson (Janssen Biotech, Inc.), Pfizer, Inc., AstraZeneca, AbbVie, Inc., Bayer AG, Ipsen Group, Sanofi, Endo Pharmaceuticals, Inc., Dendreon Corporation (Sanpower Group Co. Ltd.) and others.

The Global Prostate Cancer Therapeutics Market is segmented as given below:

Global Prostate Cancer Therapeutics Market, by Therapy
Hormone Therapy
Luteinizing Hormone-Releasing Hormone Analogs
Luteinizing Hormone-Releasing Hormone Antagonists
Antiandrogens
Chemotherapy
Systemic Chemotherapy
Regional Chemotherapy
Biologic Therapy
Targeted Therapy

Global Prostate Cancer Therapeutics Market, by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Sales
Others

Global Prostate Cancer Therapeutics Market, by Geography
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Japan
India
China
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
UAE

Read the full report: http://www.reportlinker.com/p04833605/Prostate-Cancer-Therapeutics-Market-Distribution-Channel-Hospital-Pharmacy-Retail-Pharmacy-and-Online-Sales-Global-Industry-Analysis-Size-Share-Growth-Trends-and-Forecast.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/prostate-cancer-therapeutics-market--distribution-channel---hospital-pharmacy-retail-pharmacy-and-online-sales---global-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-300442343.html


'/>"/>
SOURCE Reportlinker
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
2. Genomic Health Announces Results of Ten Studies in Breast, Prostate and Colon Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
3. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
4. Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
5. New drug proving effective in attacking advanced prostate cancer
6. AACC Annual Meeting Breaking Science Includes New Tests to Detect Life-Threatening Prostate Cancer, New Cystic Fibrosis Tests That Can Be Measured at the Point of Care, and New Ways to Determine the Safety of Drugs Used to Treat Schizophrenia and Bi
7. Berg Partners With Department of Defense Research Center and Military Medical Foundation to Advance Prostate Cancer Research
8. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
9. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
10. New Drug that Delivers Targeted Radiation Minimizes Pain and May Extend Prostate Cancer Survival
11. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):